Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Crown LiquidationCo NV in liquidatie의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Crown LiquidationCo NV in liquidatie 주요 수익원은 Diagnostics이며, 최신 수익 발표에서 수익은 36,470,354입니다. 지역별로는 United States이 Crown LiquidationCo NV in liquidatie의 주요 시장이며, 수익은 16,037,269입니다.
Crown LiquidationCo NV in liquidatie은 수익성이 있나요?
no, 최신 재무제표에 따르면 Crown LiquidationCo NV in liquidatie의 순손실은 $-35입니다.
Crown LiquidationCo NV in liquidatie에 부채가 있나요?
예, Crown LiquidationCo NV in liquidatie의 부채는 102입니다.
Crown LiquidationCo NV in liquidatie의 발행 주식은 몇 주인가요?
Crown LiquidationCo NV in liquidatie의 총 발행 주식은 29주입니다.